Lactobacillus paracasei (K71 / LP33) for Helicobacter Pylori
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Lactobacillus paracasei (K71 / LP33) in Helicobacter Pylori grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
72%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
A Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication
Finding: Adding Lactobacillus modestly increased the eradication rate (RR 1.04, 95% CI 1.01-1.07; p=0.009, high-certainty), but pooled multiple strains so no paracasei-specific effect could be isolated.
View on PubMed Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication
Finding: Across 26 studies Lactobacillus spp. as an adjunct significantly improved eradication (per-protocol RR 1.063, p<0.001) and reduced side effects, but reported no L. paracasei subgroup and the wide/heterogeneous CIs limit precision.
View on PubMed Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis
Finding: Across 34 RCTs (9,004 patients) Bifidobacterium-Lactobacillus and Bifidobacterium-Lactobacillus-Saccharomyces combinations ranked best (eradication 78.3% and 88.2%); L. paracasei was not separately identified as a top performer.
View on PubMed Fermented milk containing Lactobacillus paracasei and Glycyrrhiza glabra has a beneficial effect in patients with Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study
Finding: Fermented milk with L. paracasei HP7 plus licorice reduced 13C-UBT density (20.8% to 16.9%, p=0.035) and improved histologic inflammation, while placebo did not (p=0.130); it lowered bacterial load but did not demonstrate eradication.
View on PubMed A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy
Finding: The LP33-containing (CNCM I-1518) multi-strain product showed NO effect on antibiotic-associated diarrhea or GI symptoms; only secondary microbiota-recovery markers improved (beta-diversity p=0.02), with no eradication benefit shown.
View on PubMed Anti-Helicobacter pylori activity of a complex mixture of Lactobacillus paracasei HP7 including the extract of Perilla frutescens var. acuta and Glycyrrhiza glabra
Finding: In an animal/in-vitro model the L. paracasei HP7 mixture reduced H. pylori infection rate and gastric inflammation (lower serum IL-8); preclinical only, no human clinical endpoint.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L5a NIH Office of Dietary Supplements
Cautious
A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. source↗
L5e Specialty Society (condition-mapped)
Neutral
Interventions/Exposure: Proton pump inhibitor (PPI)-clarithromycin triple therapy, bismuth quadruple therapy (BQT), concomitant therapy, rifabutin-triple therapy, potassium-competitive acid blocker (PCAB) dual therapy, PCAB triple therapy, quinolone-based therapy, high-dose PPI dual therapy, susceptibility-guided therapy, and probiotics. source↗